Drugs and future candidates

Auteurs-es

  • Karl-Erik Andersson Institute for Regenerative Medicine, Physiology & Pharmacology, Urology, Molecular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC

DOI :

https://doi.org/10.5489/cuaj.710

Résumé

Antimuscarinic drugs are still first-line treatment for the symptoms
of overactive bladder (OAB) and are associated with good initial
response rates. Adverse effects and decreasing efficacy over
the longer term do, however, limit their overall effectiveness. As
such, alternatives to antimuscarinics are needed. The recognition
of the functional contribution of the urothelium, the spontaneous
myocyte activity during bladder filling, and the diversity of nerve
transmitters involved in the symptoms of the OAB has sparked
interest in pharmacologic manipulation of both peripheral and
central pathophysiology. Some of the treatments currently under
investigation are discussed in this review.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Biographie de l'auteur-e

Karl-Erik Andersson, Institute for Regenerative Medicine, Physiology & Pharmacology, Urology, Molecular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC

Téléchargements

Comment citer

Andersson, K.-E. (2013). Drugs and future candidates. Canadian Urological Association Journal, 5(5-S2), S131-S133. https://doi.org/10.5489/cuaj.710

Numéro

Rubrique

Review